23 Jan 2026 | 5 Mins Read
Ardelyx addresses Zydus Lifesciences acquisition speculation
Flipitmoney
Ardelyx is aware of reports about Zydus Lifesciences potentially acquiring the US company. Sources confirm Zydus Lifesciences may acquire a controlling stake or buy select molecules. Zydus Lifesciences, valued at ₹1.6 billion, plans a QIP to part-fund the acquisition, possibly up to ₹5,000 crore, to deleverage its balance sheet and evaluate US specialty business opportunities.